The burden of rheumatoid arthritis and access to treatment: determinants of access

Original paper

Abstract

As part of the study “The Burden of Rheumatoid Arthritis (RA) and Patient Access to Treatment”, this paper reviews the impact on access to RA drugs of the approval processes, pricing and funding decisions and times to market (access) in different countries. In addition, an overview of health technology assessments (HTA) and the economic literature related to RA treatments is provided. The time from approval to market access ranged from immediate to over 500 days in the countries included in the study. A total of 55 HTA reports were identified, 40 of them in the period between 2002 and 2006; 29 were performed by European HTA agencies, 14 in Canada and 7 in the United States. A total of 239 economic evaluations related to RA were identified in a specialized health economic database (HEED).

Keywords

Rheumatoid arthritis Health technology assessment Treatment access 

JEL Classification

I11 

References

  1. 1.
    Magnusson, S.: Treatment of rheumatoid arthritis—does it affect society’s cost for the disease? Br. J. Rheumatol. 35, 791–795 (1996)CrossRefGoogle Scholar
  2. 2.
    EFPIA (2002) The European Federation of Pharmaceutical Industries and Associations annual report. http://www.efpia.org/6_publ/annual/Report2002.pdf
  3. 3.
    DiMasi, J.A., Hansen, R.W., Grabowski, H.G., Lasagna, L.: Cost of innovation in the pharmaceutical industry. J. Health Econ. 10, 107–142 (1991)CrossRefGoogle Scholar
  4. 4.
    DiMasi, J.A., Hansen, R.W., Grabowski, H.G.: The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003)CrossRefGoogle Scholar
  5. 5.
    Adams, C.P., Brantner, V.V.: Estimating the cost of new drug development: is it really 802 million dollars? Health Aff (Millwood) 25, 420–428 (2006)CrossRefGoogle Scholar
  6. 6.
    Motola, D., De Ponti, F., Poluzzi, E., et al.: An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610–616 (2006)CrossRefGoogle Scholar
  7. 7.
    European Medicines Agency (EMEA). http://www.emea.eu.int
  8. 8.
    Anderson, C., McAuslane, N., Walker, S.: The impact of the changing regulatory environment on review times. CMR, International R&D briefing No.35 (online). http://www.cmr.org/pdf/r_d35.pdf (2002)
  9. 9.
    Health Canada (2005) Priority review of drug submissions. Guidance Date 30 11 2005Google Scholar
  10. 10.
    Food and Drug Administration (FDA) USA. http://www.fda.gov
  11. 11.
    Danzon, P.M., Furukawa, M.F.: Prices and availability of pharmaceuticals: evidence from nine countries. Health Aff (Millwood) (Suppl) Web Exclus. W3:521–536 (2003)Google Scholar
  12. 12.
    Pharmaceutical Price Controls in OECD Countries (2004) Implications of U.S. Consumers, Pricing, Research and Development, and Innovation. U.S. Department of Commerce International Trade Administration, Washington, DC Google Scholar
  13. 13.
    Patients W.A.I.T. Indicator (2007) Phase 6 Report. IMS Management ConsultingGoogle Scholar
  14. 14.
    National Institute for Clinical Excellence (2002) Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis. Technol. Appraisal no. 36 (March)Google Scholar
  15. 15.
    Sundhedsstyrelsen Center for Evaluering og Medicinsk Teknologivurdering. Rheumatoid Arthritis (2002) Health Technology Assessment of diagnosis and treatment. Medicinsk Teknologivurdering 4Google Scholar
  16. 16.
    Coyle, D., Judd, M., Blumenauer, B., et al.: Infliximab and etanercept in patients with rheumatoid arthritis: a systematic review and economic evaluation (Technology report no 64). Canadian Coordinating Office for Health Technology Assessment, Ottawa (2006)Google Scholar
  17. 17.
    National Institute for Clinical Excellence (2003) Anakinra for rheumatoid arthritis. Technol. Appraisal 72 (November)Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • J. Lundqvist
    • 1
  • F. Kastäng
    • 1
  • G. Kobelt
    • 2
  • B. Jönsson
    • 3
  1. 1.i3/InnovusStockholmSweden
  2. 2.Department of OrthopedicsUniversity of LundLundSweden
  3. 3.Department of EconomicsStockholm School of EconomicsStockholmSweden

Personalised recommendations